CME Board Member
Steve d’Incelliis a Managing Director at SK Capital, a private investment firm in the specialty chemicals, materials and pharmaceuticals sectors. He advances the investment strategy and execution focusing on both specialty and fine chemicals. Board member at CME, Noramco, and Wavelength Pharmaceuticals.
Working collaboratively with management to support the realization of their strategic, operational and financial objectives, Mr. d’Incelli plays an active role in all aspects of the firm’s investment strategy and execution focusing on both the specialty and fine chemicals industries and currently serves on the Board of Directors of Perimeter Solutions, Noramco, Inc. and Tasmanian Alkaloids and Wavelength Pharmaceuticals. Prior to joining SK Capital in 2015, Mr. d’Incelli was a Vice President at Sun Capital Partners where he played a significant role in sourcing and executing a variety of acquisitions as well as active board-level responsibilities for several of Sun Capital’s portfolio companies. Before joining Sun Capital, he worked in the Global Leverage Finance group at Lehman Brothers. Mr. d’Incelli earned a Bachelor of Arts in Economics with a minor in Psychology from Northwestern University.